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The effects of vitamin D2 (VD2) on hypocalcemia were studied in 54 hypo calcemic patients (29 males and 25 females) on chronic hemodialysis. Calcium lactate (3 g/day) or VD2 (10,000 IU/day, 50,000 IU/day and 80,000 IU/day) were administered for 4 months in order to correct the hypocalcemia. Serum calcium, phosphate and alkaline phosphatase levels were measured and the effects of VD2 on these parameters of calcium metabolism were followed. 1) Calcium lactate or 10,000 IU/day of VD2 were not effective for the correction of hypocalcemia, while 50,000-80,000 IU/day of VD2 were effective. The effects of VD2 on serum calcium concentrations were dose-dependent, and the normaliza tion of serum calcium concentrations was achieved more rapidly with higher doses of VD2. However, in the group treated with 80,000 IU/day of VD2, many patients developed hypercalcemia, but in the group treated with 50,000 IU/day of VD2, only a few patients did it. From these results, suitable dose (initial and maintenance doses) of VD2 in dialysed patients would be 50,000 IU/day. 2) When the responder group (normal serum calcium levels after 4 months of treatment with 50,000 IU/ day of VD2) and the non-responder group serum calcium levels lower than 4.2 mEq/liter on the same condition) were compared, the durations of dialysis were significantly shorter in the former than those in the latter. This fact may suggest that the effects of VD2 administration on hypocalcemia in dialysed patients are partly dependent on the residual renal function concerning the conversion of 25-OH-D3 into 1,25 (OH)2D3.
--chronic dialysis treatment; hypocalcemia; vitamin D2 supplementation patient to keep the normal electrolytes balance. The calcium concentration was kept constant (3.5 mEq/liter).
The dialysate supplying system was composed of a 50-liters tank and recirculation system, so that the fluid and electrolytes dialysed out of the body were easily calculated at the end of the dialysis.
The removed substances were routinely analysed and recorded in each dialysis.
Statistical analysis was carried out using unpaired or paired t-test. Table 2 presents the effects of calcium lactate or VD2 (10,000 IU/day, 50,000 IU/day, and 80,000 IU/day) on serum calcium concentrations in the serial determinations during four months of treatment and the levels of significance (p) in paired t-test.
RESULTS
In the group treated with calcium lactate, significant effects were not recogniz ed throughout the periods. In the group treated with 10,000 IU/day of VD, statistically significant effects were found after 1 and 3 months, but in other periods no effects were obtained.
On the contrary, in the group treated with 50,000-80,000 IU/day of VD,, statistically significant effects were found in every period.
In the group treated with calcium lactate and 10,000 IU/day of VD, develop ment of hypercalcemia was never observed. But, in the group treated with 50,000 IU/day of VD2, 1 patient (4%) showed hypercalcemia after 2 months of treatment, 2 patients (9%) after 3 months, and 1 patient (4%) after 4 months. In the group treated with 80,000 IU/day of VD2, 3 patients (11%) showed hypercalcemia after 2 months of treatment, 2 patients (2%) after 3 months, and 8 patients (29%) after 4 months. Table 3 compares the results in the responder group (normal serum calcium concentration after 4 months of 50,000 IU/day of VD, administration) and the non-responder group (serum calcium levels lower than 4.2 mEq/liter on the same condition). The number of patients in the former was 13 (57%) and that in the latter was 10 (43%).
The mean serum calcium concentration in the former was 4.6 mEq/liter and that in the latter was 3.8 mEq/liter. The mean age in the former was 34.7 and that in the latter was 43.0 and the difference was not significant. The mean duration of the dialysis in the former was 15.2 months and that in the latter was 34.4 and the difference was significant (p<0.025). Table 4 shows the changes of the serum phosphate and alkaline phosphatase levels before and after VD2 (50,000 IU/day) administration. In both parameters, no significant differences between the values before and after the treatment were recognized by paired t-test.
DISCUSSION
Abnormal calcium metabolism and renal osteodystrophy in patients on chronic hemodialysis are the most troublesome problems for both patients and physicians. Major symptoms related to these abnormal calcium metabolism in long-term dialysis are as follows: osteomalacia, and other complications of secondary hyperpara thyroidism (hypercalcemia, metastatic calcification, and pruiritis). It is well recognized that these abnormal calcium metabolism is primarily due to defective formation of 1, 25 We have treated patients by hemodialysis using dialysate containing a fixed calcium concentration (3.5 mEq/liter) since 1972. To correct negative calcium balance in patients on chronic hemodialysis, VD2 has been used in our hemodialysis unit.
As to the doses of VD2, 100,000-300,000 IU/day were to be proper in the report of Lumb et al. (1971) , 50,000-100,000 IU/day in that of Johnson et al. (1977) , and 600,000 IU/day in that of Brancaccino et al. (1977) . However, Witer et al. (1976) reported that in a non-dialysed girl (14 years of age) with chronic renal failure, 13,000-28,000 IU/day of VD2 supplementation for 5 months were not effective for the correction of hypocalcemia and renal bone diseases.
According to our experiences in 6 years, 100,000-300,000 IU/day of VD2 caused hypercalcemia in most of the patients treated.
Thus, we tried to determine the appropriate dose of VD2 required for the correction of serum calcium concentration in Japanese patients on chronic hemodialysis. The effects of VD2 on serum calcium concentration were also investigated.
From the results obtained, the following discussions seem to be warranted.
Appropriate doses of VD2 in the patients on chronic hemodialysis Calcium lactate or 10,000 IU/day of VD2 were not effective for the correction of hypocalcemia, but 50,000-80,000 IU/day of VD2 were effective. Thus, the effects of VD2 were dose-dependent, and the normalization of serum calcium was achieved more rapidly with higher doses. Hypercalcemia was never observed in the group treated with calcium lactate and 10,000 IU/day of VD, but it occurred in a few patients treated with 50,000 IU/day of VD2. However, in the group treated with 80,000 IU/day of VD2, many patients developed hypercalcemia, and the treatment had to be discontinued.
From these results, it may be concluded that the suitable dose of VD2 should be around 50,000 IU/day.
Responsiveness of serum calcium to VD2
Patients of the responder group (normal serum calcium concentrations after 4 months of the treatment of 50,000 IU/day of VD,) had significantly shorter dura tions of dialysis treatment (averaging 15 months) as compared with those (averaging 34 months) in non-responder group (lower than 4.2 mEq/liter of serum calcium concentrations on the same condition).
This fact may indicate that 1,25 (OH)2D3 is synthesized in proportion to the residual renal function and it acts as a most effective regulator in the metabolism of calcium. 
